Go further with cancer screening

Introducing Galleri®, the first-of-its-kind multi-cancer early detection test that looks for a signal shared by 50+ types of cancer with a single blood test.1

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

What is the Galleri test?

Galleri redefines what’s possible. Only 5 cancers have recommended screening tests.2 Using Galleri in addition to these tests can increase the chance of finding cancer early, to allow for earlier treatment.1,3

With a single blood test, Galleri screens for a signal shared by multiple cancers that would otherwise go unnoticed.1,4 If a cancer signal is detected, Galleri predicts the tissue type or organ associated with the cancer signal with 88% accuracy* to help guide follow-up diagnostic testing which may include lab work or imaging to confirm cancer.4

*In the PATHFINDER study, Cancer Signal Origin (CSO) prediction accuracy was 88% for participants with a cancer diagnosis among study participants with a "Cancer Signal Detected" test result.

Person in purple top with stethoscope holding a Galleri box with a Time Best Inventions 2022 banner flag over the image.

Who is Galleri for?

Age is the biggest risk factor for cancer. In fact, adults over age 50 are 13 times more likely to have cancer compared to people under the age of 50.5 Cancer risk increases for everyone as they age regardless of family history—only 5% to 10% of cancers are inherited.5,6

The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.

  • The Galleri test is available by prescription only.

  • Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

white man with short gray hair in gray top and jeans sitting on a couch in front of an open window with his arm around a blonde woman in blue jumpsuit
a bald Black man in a denim button up shirt talking to his partner in their kitchen, a Black woman wearing black cat eye glasses and a blue and pink striped shirt, with a cup of coffee and a tablet on the counter in front of them



I am interested in learning more about the Galleri test

white male doctor in lab coat and stethoscope sitting behind a desk and talking to a white blonde female patient in a blue striped shirt

Healthcare Providers

Healthcare Providers

I am a healthcare provider interested in offering the Galleri test to my patients

Black woman in a white polka dot shirt with a tan jacket smiling and sitting at a table with a notebook and pen talking to an Asian woman in a blue and black shirt



I represent an employer interested in offering the Galleri test to my organization’s employees

group of healthcare professionals talking and sitting at a table in front of a window with tablets and notepads

Health Systems

Health Systems

I represent a health system interested in making the Galleri test available to my patient population

Early detection makes a difference

purple text indicating approximately seventy percent.

Around 70% of cancer deaths* are caused by cancers without recommended screenings.7

5 circles with graphics inside indicating breast, color, lung, cervical, and prostate cancers

Today, there are 5 recommended cancer screening tests.2 Adding Galleri helps screen for more cancers, including cancers that do not have recommended screening.1,3

purple text indicating 2x

In a clinical study, Galleri approximately doubled the number of cancers detected with recommended screening.3

*Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).

**For those at risk.

Galleri should be used in addition to healthcare provider recommended screening tests.

Supported by robust clinical data, Galleri sets the standard for multi-cancer early detection

20,000+ individuals participated in large clinical studies1,4
Text reading: "GRAIL collaborated with leading cancer institutes to study the Galleri test" followed by logos for the Cleveland Clinic, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Intermountain Healthcare, Icahn School of Medicine at Mount Sinai, Sutter Health, UHN Princess Margaret Cancer Centre, Benoroya Research Institute Virginia Mason, Sarah Cannon, Hartford HealthCare Cancer Institute, The US Oncology Network, Knight Cancer Institute, The Christ Hospital Lindner Research Center

Have more questions?

Please answer the following questions to fill in the appropriate form.

You can also contact us at (833) 694‑2553 or use the chat feature on the bottom-right of this page for additional help.

  1. What describes you best?

  2. What are you looking for?

  3. Fill in the form

    We care about your privacy. Our Privacy Policy

    Billing Support

    This form is for billing questions only. If you need general customer support, please choose one of the other forms or use the chat option at the bottom of your screen.

    We care about your privacy. Our Privacy Policy

    We care about your privacy. Our Privacy Policy

    Please login to the Provider Portal if you are already an ordering provider.

    Please include information for a primary contact at your practice, should any questions come up during order processing.

    Click here to copy provider information below as the primary contact

    We care about your privacy. Our Privacy Policy

    We care about your privacy. Our Privacy Policy

    If you are a concierge, private, or group practice provider, complete this form instead.

    We care about your privacy. Our Privacy Policy

    We care about your privacy. Our Privacy Policy

    Do you represent a first responder or firefighter organization? Use this form instead.

    We care about your privacy. Our Privacy Policy

    This form is meant for firefighter and first responder organizations only

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-77. DOI:https://doi.org/10.1016/j.annonc.2021.05.806.

  2. US Preventive Services Task Force. Recommendations Cancer. Accessed 7Mar2023. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results.

  3. Schrag D, McDonnall CH, Naduld L, et al. PATHFINDER: A Prospective Study of a Multi-Cancer Early Detection Blood Test. Presentation at European Society of Medical Oncology (ESMO) Congress September 9-13, 2022; Paris, France.

  4. Hubbell E, Venn O, Shanmugam A. Shared Cancer Signal: Evidence from Cross-Training. Presentation at USC Computational Biology Symposium; May 19-21, 2022; Los Angeles, CA.

  5. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database Incidence - SEER Research Limited-Field Data, 21 Registries, Nov 2020 Sub (2000-2018) - Linked To County Attributes -Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2021, based on the November 2020 submission. Risk Factor Data on file: American Cancer Society Cancer Prevention Studies II/III.

  6. NIH/National Cancer Institute. Genetic testing for inherited cancer susceptibility syndromes. Accessed 3Mar2023. https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet.

  7. American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022 https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html. Data on file GA-2021-0065.